Abstract
Introduction: Guselkumab(GUS) demonstrated efficacy in the Ph3 DISCOVER-1&2 trials in patients with psoriatic arthritis. Here, the effect of GUS on fatigue is evaluated in these trials using Functional Assessment of Chronic Illness Therapy-Fatigue(FACIT-F).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
